SEARCHOTHERoncology, clinical trial

other·oncology, clinical trial, research methods, public health, internal medicine·PMC10647159

Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design

BMC Cancer · 21 authors, 8 centres

AI SUMMARY

FIDELITY 100%

POPULATIONNon-metastasized female primary breast cancer patients who are curatively treated and start follow-up care

INTERVENTIONPersonalized surveillance plans (PSPs) and personalized aftercare plans (PAPs)

COMPARISONCare as usual

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This protocol describes a prospective study testing personalized surveillance and aftercare plans for non-metastasized breast cancer patients to see if they reduce cancer worry and improve quality of life compared to standard care.

Full summary

715 CHARS

The NABOR study is a prospective, multicenter trial using a multiple interrupted time series design across 10 hospitals. It aims to evaluate the cost-effectiveness of personalized follow-up care for non-metastasized breast cancer patients. The intervention involves transitioning from standard care to personalized surveillance and aftercare plans, which are tailored using prediction tools and patient decision aids. The primary outcomes are patient-reported cancer worry and self-rated quality of life, measured at five points over two years. The protocol is described as currently recruiting, with no results yet reported. Findings will inform future evidence-based guidelines for personalized survivorship care.

PICO

PPOPULATION

Non-metastasized female primary breast cancer patients who are curatively treated and start follow-up care

IINTERVENTION

Personalized surveillance plans (PSPs) and personalized aftercare plans (PAPs)

OOUTCOME

Patient-reported cancer worry (Cancer Worry Scale) and overall quality of life (EQ-VAS score)

STUDY TYPE

other

SPECIALTY

oncology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10647159

Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design

BMC Cancer

READ THE FULL PAPER

ABSTRACT

Background Follow-up of curatively treated primary breast cancer patients consists of surveillance and aftercare and is currently mostly the same for all patients. A more personalized approach, based on patients’ individual risk of recurrence and personal needs and preferences, may reduce patient burden and reduce (healthcare) costs. The NABOR study will examine the (cost-)effectiveness of personalized surveillance (PSP) and personalized aftercare plans (PAP) on patient-reported cancer worry, self-rated and overall quality of life and (cost-)effectiveness. Methods A prospective multicenter multiple interrupted time series (MITs) design is being used. In this design, 10 participating hospitals will be observed for a period of eighteen months, while they -stepwise- will transit from care as usual to PSPs and PAPs. The PSP contains decisions on the surveillance trajectory based on individual risks and needs, assessed with the ‘Breast Cancer Surveillance Decision Aid’ including the INFLUENCE prediction tool. The PAP contains decisions on the aftercare trajectory based on individual needs and preferences and available care resources, which decision-making is supported by a patient decision aid. Patients are non-metastasized female primary breast cancer patients ( N = 1040) who are curatively treated and start follow-up care. Patient reported outcomes will be measured at five points in time during two years of follow-up care (starting about one year after treatment and every six months thereafter). In addition, data on diagnostics and hospital visits from patients’ Electronical Health Records (EHR) will be gathered. Primary outcomes are patient-reported cancer worry (Cancer Worry Scale) and overall quality of life (as assessed with EQ-VAS score). Secondary outcomes include health care costs and resource use, health-related quality of life (as measured with EQ5D-5L/SF-12/EORTC-QLQ-C30), risk perception, shared decision-making, patient satisfaction, societal participation, and cost-effectiveness. Next, the uptake and appreciation of personalized plans and patients’ experiences of their decision-making process will be evaluated. Discussion This study will contribute to insight in the (cost-)effectiveness of personalized follow-up care and contributes to development of uniform evidence-based guidelines, stimulating sustainable implementation of personalized surveillance and aftercare plans. Trial registration Study sponsor: ZonMw. Retrospectively registered at ClinicalTrials.gov (2023), ID: NCT05975437 .

CITATION EXPORT

A. Klaassen-Dekker, C. H. C. Drossaert, M. C. Van Maaren et al.. Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design. BMC Cancer. (2023). https://doi.org/10.1186/s12885-023-11504-y

AUTHORS

21 · 8 CENTRES

A. Klaassen-Dekker, C. H. C. Drossaert, M. C. Van Maaren, A. E. Van Leeuwen-Stok, V. P. Retel, J. C. Korevaar, S. Siesling, B. Knottnerus, C. Guerrero-Paez, J. Burgers, A. Zeillemaker, M. J. Vrancken, M. Van Hezewijk, E. Siemerink, A. Honkoop, J. Veltman, R. Mann, J. Wiegersma, S. Claassen, M. Van der Lee, N. Van Uden

1https://ror.org/006hf6230grid.6214.10000 0004 0399 8953Health Technology and Services Research Department, Technical Medical Centre, University of Twente, Enschede, The Netherlands
2https://ror.org/03g5hcd33grid.470266.10000 0004 0501 9982Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands
3https://ror.org/006hf6230grid.6214.10000 0004 0399 8953Health & Technology Department, University of Twente, Enschede, The Netherlands
4https://ror.org/04cr37s66grid.476173.0Dutch Breast Cancer Research Group, BOOG Study Center, Utrecht, The Netherlands
5https://ror.org/03xqtf034grid.430814.a0000 0001 0674 1393Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands
6https://ror.org/057w15z03grid.6906.90000 0000 9262 1349Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
7https://ror.org/021zvq422grid.449791.60000 0004 0395 6083Faculty of Health, Nutrition & Sport, The Hague University of Applied Sciences, The Hague, The Netherlands
8https://ror.org/015xq7480grid.416005.60000 0001 0681 4687Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands